| KS OmniScriptum Publishing

87,530원  | 20210408  | 9786203607055

RESUMET-DM1 e o primeiro de um novo medicamento experimental contra o cancro conhecido como um conjugado antifarmaco. O T-DM1 e uma substancia quimioterapica que combina dois medicamentos cancerigenos existentes para administrar ambos especificamente as celulas cancerigenas: Trastuzumab, um anticorpo monoclonal que visa as celulas que produzem em excesso a proteina HER2; e, o T-DM1 e uma substancia quimioterapica.

 | KS OmniScriptum Publishing

87,530원  | 20210412  | 9786203607024

RESUMET-DM1 e il primo di un nuovo farmaco sperimentale contro il cancro noto come coniugato anticorpo-farmaco. Dimostra un miglioramento della sopravvivenza libera da progressione rispetto alla terapia standard nel cancro al seno metastatico HER2-positivo.

 | KS OmniScriptum Publishing

87,530원  | 20210408  | 9786203606997

RESUMET-DM1 ist der erste Vertreter eines experimentellen neuen Krebsmedikaments, das als Antikorper-Wirkstoff-Konjugat bekannt ist. Es zeigt eine Verbesserung des progressionsfreien Uberlebens gegenuber der Standardtherapie bei HER2-positivem metastasierendem Brustkrebs.

 | KS OmniScriptum Publishing

87,530원  | 20210408  | 9786203607000

RESUMET-DM1 is the first of an experimental new cancer drug known as an antibody-drug conjugate. It demonstrates an improvement in progression-free survival over standard therapy in HER2-positive metastatic breast cancer. It combines two existing cancer drugs in order to deliver both drugs specifically to cancer cells: Trastuzumab, a monoclonal antibody to target cells that overproduce the HER2 protein; and, T-DM1 is a chemotherapeutic substance.

 | Sciencia Scripts

87,530원  | 20210408  | 9786203607062

RESUMET-DM1 является первым из экспериментальных новых онкологических препаратов, известных как конъюгат антител к лекарственным препаратам. Он демонстрирует улучшение выживаемости без прогрессии по сравнению со стандартной терапией при HER2-положительном метастатическом р?

 | KS OmniScriptum Publishing

87,530원  | 20210408  | 9786203607048

RESUMET-DM1 jest pierwszym z eksperymentalnych nowych lekow przeciwnowotworowych, znanych jako koniugat przeciwciało-lek. Wykazuje on popraw? prze?ycia wolnego od progresji choroby w porownaniu ze standardow? terapi? w HER2-dodatnim przerzutowym raku piersi.

 | Lulu.com

13,960원  | 20130125  | 9781300671398

The Dark man: The Journal of Robert E. Howard Studies, Vol. 7, No. 1, December 2012. Contents: Prefatory Remarks By Mark E. Hall Articles The Writer's Style: Sound and Syntax in Howard's Sentences By David C. Smith "I 'n' I A-Liberate Zimbabwe": Motifs of Africa and Freedom in Howard's "The Grisly Horror" By Patrick R. Burger Robert E. Howard and the Lone Scouts By Rob Roehm Reviews by Charles Hoffman and Charles Gramlich.